The global prevalence of neurologic disorders is rising, and yet weare still unable to deliver most drug molecules, in therapeutic quantities, to the brain. The blood brain barrier consists of a tight layer of endothelial cells surrounded by astrocyte foot processes, and these anatomic features constitute a significant barrier to drug transport from the blood to the brain. One way to bypass the blood brain barrier and thus treat diseases of the brain is to use the nasal route of administration and deposit drugs at the olfactory region of the nares, from where they travel to the brain via mechanisms that are still not clearly understood, with travel across nerve fibers and travel via a perivascular pathway both being hypothesized. This article will emphasise on properties of Blood Brain Barrier, strategies to overcome the blood–brain barrier, literature regarding the use of SLNs in various neurological disease states, production methods of SLN and its evaluation. Hence, these solid lipid formulations can be a new form and one of the promising approaches for drug delivery system in future, that have remarkable possibility to cross the BBB.
Cite this article:
Harsh Joshi, Priyanka Ahlawat. Solid Lipid Nanoparticles for nose to Brain delivery: A Review. Res. J. Pharma. Dosage Forms and Tech.2021; 13(1):57-61. doi: 10.5958/0975-4377.2021.00010.0
Harsh Joshi, Priyanka Ahlawat. Solid Lipid Nanoparticles for nose to Brain delivery: A Review. Res. J. Pharma. Dosage Forms and Tech.2021; 13(1):57-61. doi: 10.5958/0975-4377.2021.00010.0 Available on: https://rjpdft.com/AbstractView.aspx?PID=2021-13-1-10
1. Alam MI, BabootaS, AhujaA, AliM, AliJ, Sahni JK, etal. Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. Int JPharm 2014;470: 99–106.
2. Bhanushali RS, Gatne MM, Gaikwad R V, Bajaj AN, Morde MA., (2015). Nanoemulsion based Intranasal Delivery of Antimigraine Drugs for Nose to Brain Targeting; 71(6):707-709. British Journal of Pharmacology, 2009, 656-665.
3. Chen Y, Liu L., (2012). Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev.; 64(7): 640-665.
4. Desai P, Patravale V, Date A, “Overcoming poor oral bioavailability using nanoparticle formulations opportunities and limitations”, Drug discovery technologies, vol. 9, issue 2, 2012.
5. Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99: 1654–73. dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. ‖ extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex‖,
6. Fazil M, MdS, HaqueS, KumarM, BabootaS, Sahni JK, etal. Development and evaluation of rivastigmine loaded chitosan nano-particles for brain targeting. EurJPharmSci 2012; 47: 6–15.
7. Filiano AJ, Gadani SP, Kipnis J., (2014). Interactions of innate and adaptive immunity in brain development and function. Brain Res. 2015;1617: 18-27.
8. Gaillard PJ, Visser CC, Appeldoorn CCM, Rip J., (2012). Enhanced brain drug delivery: Safely crossing the blood-brain barrier. Drug Discov Today Technol.;9(2): e155-e160.
9. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. (2013). Origin and differentiation of microglia. Front Cell Neurosci.; 7(April):45.
10. Gizurarson S (2012). Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9(6): 566-582.
11. Gizurarson S (2012). Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9(6): 566-582.
12. Gizurarson S (2012). Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9(6): 566-582.
13. GW K. The First Line of Defense in Brain Pathologies. (1995). Drug Res (Stuttg) ;45(1): 357–360.
14. Heckers S, Barch DM, Bustillo J, Gaebel W, Gur R, Malaspina D, et al. Structure of the psychotic disorders classification in DSM-5. Schizophr Res. 2013; 150:11–4.
15. Heidi M, Mansour MS, Abeer AG and Patrick PD, ―Materials for pharmaceutical
16. Helen L. Rowley and Patricia L. Needham, ―A comparison of the acute effects of
17. Ikeda M, Bhattacharjee AK, Kondoh T, Nagashima T, Tamaki N (2002), Synergistic effect of cold mannitol and Na(+)/Ca(2+) exchange blocker on blood-brain barrier opening. Biochem Biophys Res Commun.;291(3):669-674. Int. J. Mol. Sci. 2010, 11, 3298-3322.
18. Javed Ali, -Bromocriptine loaded chitosan nanoparticles intended for direct nose tobrain delivery: Pharmacodynamic and pharmacokinetic study in mice model‖, Eur. J.
19. Joel G. Hardman, Lee E. Limbird,” Gooman and Gilman’s, “The Pharmacological basis of therapeutics,10th edition, Medical Publishing division, 2001, pp 1349-1372.
20. K PS, S WK, Kamlesh M, T BD, K JD, Pharmacy C, et al. Development and evaluation of solid lipid nanoparticles containing anti-migraine drug. World J Pharm Sci. 2014; 2:1014–21.
21. Kaur IP, Bhandari R, Bhandari S, Kakkar V., (2008). Potential of solid lipid nanoparticles in brain targeting. J Control Release.;127(2):97-109.
22. Krol S., (2012). Challenges in drug delivery to the brain: Nature is against us. J Control Release. 2012;164(2):145-155.
23. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K., (2008) Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm.;358(1-2):285-291.
24. Kumar R, Yasir M, Saraf SA, Gaur PK, Kumar Y, Singh AP. Glyceryl monostearate based nanoparticles of mefenamic acid: fabrication and in vitro characterization. Drug Invention Today 2013;5: 246–50
25. Li X, Tsibouklis J, Weng T, Zhang B, Yin G, Feng G, et al. Nano carriers for drug transport across the blood–brain barrier. J Drug Target. 2017; 25:17–28.
26. Michele Trotta, Francesca Debernardi, Otto Caputo “Preparation of solid lipid nanoparticles by a solvent emulsification- diffusion technique” International Journal of Pharmaceutics
27. Mistry A, Stolnik S, Illum L., (2009). Nanoparticles for direct nose-to-brain delivery of drugs; 379:146-157.
28. Mohd Yasir, Udai Vir Singh Sara, Iti Chauhan, Praveen Kumar Gaur, Alok Pratap Singh, Dinesh Puri and Ameeduzzafar “Solid lipid nanoparticles for nose to brain delivery of donepezil: formulation, optimization by Box–Behnken design, in vitro and in vivo evaluation” Journal Artificial Cells, Nanomedicine, and Biotechnology
29. Mukthinuthalapati, Mathrusri Annapurna “New Spectrophotometric Techniques for the Quantification of Zotepine – An Antipsychotic Drug”
30. Muller RH, Karsten Mader K, and Gohla S,“Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art” Eur.J.Pharma.BioPharma , 2000,50, pp 16-177
31. Needham PL, Atkinson J, Skill MJ, Heal DJ. Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol Bull. 1996;32: 123–8.
32. Pang Z, Lu W, Gao H, et al., (2008). Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release. 2008;128(2):120-127.
33. Park K. (2008). Trojan monocytes for improved drug delivery to the brain. J Control Release. ;132(2):75.
34. Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B. (2008). Neocortical glial cell numbers in human brains. Neurobiol Aging.;29(11):1754-1762. Pharmaceu. Sci. 48, 2013, 393-405.
35. Qin LJ, Gu YT, Zhang H, Xue YX. (2009). Bradykinin-induced blood-tumor barrier opening is mediated by tumor necrosis factor-α. Neurosci Lett. 2009;450(2):172-175.
36. Rang HP; Dale MM; Ritter JM and Flower RJ. Pharmacology; 6th Edn; Churchill Living
37. Rausch DM, Stover ES., (2011). Neuroscience research in AIDS. Prog Neuro- Psychopharmacology Biol Psychiatry. 2001;25(1):231-257.
38. Rohit B, Pal KI., (2013). A Method to Prepare Solid Lipid Nanoparticles with Improved Entrapment Efficiency of Hydrophilic Drugs. Curr Nanosci.;9(2):211-220.
39. S Yamamura, K Ohoyama, M Nakagawa and D Sujuki, -Effect of Zotepine on
40. Saindane NS, Pagar KP, Vavia PR. Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization. AAPS PharmSciTech. 2013;14: 189–99. Schmiedeberg’s Arch Pharmacol, 361, 2000, 187-192.
41. SchwarzC, MehnertW, LucksJS, MullerRH. Solid lipid nanopar-ticles (SLN) for controlled drug delivery.I. production, characteriza-tion and sterilization. J ControlRelease 1994; 30:83–96.
42. SerralheiroA, AlvesG, FortunaA, FalcãoA. Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting. EurJPharmSci 2014;60: 32–9.
43. Shadab Md, Rshid A. Khan, Gulam Mustafa, Krishna Chuttani, Sanjula Baboota and Singh AK SA and MN (2012). Nasal cavity: A promising platform for drug delivery and research approaches from nasal to brain targeting. J drug del ther.;2(3):22-33.
44. Singh AP, Saraf SK, Saraf SA. SLN approach for nose-to-brain delivery of alprazolam. Drug DelivTranslRes 2012;2: 498–507.
45. Sood S, Jain K, Gowthamarajan K., (2014). Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surfaces B Biointerfaces;113: 330-337.
46. Sozio P, Cerasa LS, Laserra S, et al., (2013). Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer’s disease. Eur J Pharm Sci.;49(2):187-198.
47. Sravanthi Reddy Pailla and Sreekanth Talluri and Nagarjun Rangaraj and Ramdas Ramavath and Veerabhadra Swamy Challa and Nandkumar Doijad and Sunitha Sampathi “Intranasal Zotepine Nanosuspension: intended for improved brain distribution in rats” DARU Journal of Pharmaceutical Sciences Stone Publication, Philadelphia, 2007, Page no.:545.